Vetrx Formulations Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.10 M
- Company Age 7 Year, 6 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 2.00 M
- Revenue Growth -2.91%
- Profit Growth -45.98%
- Ebitda -23.67%
- Net Worth 9.70%
- Total Assets -14.19%
About Vetrx Formulations
Vetrx Formulations Private Limited (VFPL) is a Private Limited Indian Non-Government Company incorporated in India on 13 July 2017 (Seven years and six months 20 days old ). Its registered office is in Kanpur Nagar, Uttar Pradesh, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹2.00 M.
Sanjeev Mishra and Shipra Tripathi serve as directors at the Company.
Company Details
- Location
Kanpur Nagar, Uttar Pradesh, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media-
Corporate Identity Details
- CIN/LLPIN
U51909UP2017PTC094955
- Company No.
094955
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
13 Jul 2017
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Kanpur
Industry
Who are the key members and board of directors at Vetrx Formulations?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sanjeev Mishra  | Director | 13-Jul-2017 | Current |
| Shipra Tripathi | Director | 13-Jul-2017 | Current |
Financial Performance of Vetrx Formulations.
Vetrx Formulations Private Limited, for the financial year ended 2022, experienced Minor drop in revenue, with a 2.91% decrease. The company also saw a substantial fall in profitability, with a 45.98% decrease in profit. The company's net worth moved up by a moderate rise of 9.7%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Vetrx Formulations?
In 2022, Vetrx Formulations had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹2.00 M
₹0
Charges Breakdown by Lending Institutions
- Hdfc Bank Limited : 0.20 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 24 Jun 2024 | Hdfc Bank Limited | ₹2.00 M | Open |
How Many Employees Work at Vetrx Formulations?
Vetrx Formulations has a workforce of 4 employees as of Apr 06, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Vetrx Formulations, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Vetrx Formulations's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.